z-logo
Premium
Serum NT ‐pro CNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia
Author(s) -
Kubota Takuo,
Wang Wei,
Miura Kohji,
Nakayama Hirofumi,
Yamamoto Keiko,
Fujiwara Makoto,
Ohata Yasuhisa,
Tachibana Makiko,
Kitaoka Taichi,
Takakuwa Satoshi,
Miyoshi Yoko,
Namba Noriyuki,
Ozono Keiichi
Publication year - 2016
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.13025
Subject(s) - medicine , achondroplasia , endocrinology , short stature , biomarker , idiopathic short stature , natriuretic peptide , hormone , growth hormone , biology , pediatrics , heart failure , biochemistry
Summary Objective Serum amino‐terminal propeptide of C‐type natriuretic peptide ( NT ‐pro CNP ) levels have been proposed as a biomarker of linear growth in healthy children. The usefulness of NT ‐pro CNP in patients with achondroplasia ( ACH )/hypochondroplasia ( HCH ) remains to be elucidated. The objective was to study whether serum NT ‐pro CNP level is a good biomarker for growth in ACH / HCH and other patients of short stature. Design This was a longitudinal cohort study. Patients Sixteen children with ACH (aged 0·4–4·3 years), six children with HCH (2·7–6·3 years), 23 children with idiopathic short stature ( ISS ) (2·2–9·0 years), eight short children with GH deficiency ( GHD ) (2·9–6·8 years) and five short children born small for gestational age ( SGA ) (2·0–6·6 years). Patients with ACH / HCH received GH treatment for 1 year. Measurements Serum NT ‐pro CNP levels and height were measured. Results NT ‐pro CNP levels positively correlated with height velocity in these short children ( P < 0·05, r = 0·27). NT ‐pro CNP levels inversely correlated with age in children with ISS alone ( P < 0·01, r = −0·55). Serum NT ‐pro CNP levels in patients with ACH / HCH were increased 3 months following the initiation of GH treatment ( P < 0·05). Height SDS gain during GH treatment for 1 year was positively correlated with the changes in NT ‐pro CNP levels after the initiation of GH ( P < 0·01, r = 0·72). Conclusion Serum NT ‐pro CNP levels may be a good biomarker to indicate the effect of GH treatment on growth in patients with ACH / HCH at least in the first year and height velocity in short stature patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here